ICI [Immune checkpoint inhibitor] induced autoimmune diabetes shows similarity with type 1 diabetes that develops autoimmunity in healthy tissue of cancer patient is the side effect of immunotherapy.
Our findings have great promise in being able to establish personalized cancer medicine specialized for tumor recurrence and create novel inhibitors that restore tumor response to immunotherapy.
A Dana-Farber-led trial shows pembrolizumab before and after surgery significantly boosts event-free survival in early-stage TNBC—marking the first major progress in over 20 years.